Cécile Thébault

Functions as a College/University

Sofimac Régions is an active manager which specializes in making equity investments in unlisted small businesses mainly based in the Auvergne, Rhône-Alpes, Limousin, and Provence-Alpes-Côte d'Azur regions in France. The firm invests in businesses in the technology and industrial sectors at all stages of development, from seed capital to buyouts. Sofimac Régions seeks to identify companies with good growth and valuation potential and carries out campaigns to identify potential investee companies. The firm analyzes potential investee company management, products, markets and strategy, as well as their historical and forecast financial statements and financing needs. The firm monitors investments through regular contacts with company management, assisting them with their strategic thinking. Their exit may be the sale of the company, a secondary buyout or an IPO. Sofimac Régions seeks to set up new innovative, high technology companies based on scientific, technological and marketing criteria as well as the founder's ability to successfully implement his corporate plan. The firm may co-invest alongside other seed or early-stage venture capital funds, investing within a framework of organizations that support innovation. They fund the costs of building a prototype and invest additional funds to mass produce and market the product if successful at the end of the seed stage. They evaluate start-up and early-stage projects in terms of technology, intellectual property rights, products and markets, choosing business plans based on the company's management capabilities and the potential to market their technology and products internationally. Sofimac Régions participates in investee company development through organic growth, acquisitions and ownership transfers in the manufacturing and services sectors, investing in companies with high growth potential. The firm coordinates financial engineering and maintains close relations with the investee company's management, providing financing over the medium-term with the aim of exiting after five to seven years.

Develops biopharmaceutical products

Researches and develops diagnostic tools for monitoring immune cell repertoire

Manufactures medical devices based on collagen technology

Operates as a biopharmaceutical company that develops drugs for treatment of central nervous system diseases

Operates as a biotechnology company which produces organic and carboxylic acids

Engages in breeding of insects as a protein substitute for animal feed